Reckitt Benckiser Group’s fair value estimate has been nudged up from about £62.50 to roughly £63.15 per share, as analysts grow slightly more confident in the company’s long term revenue trajectory. With the discount rate steady at 7.07% and long run revenue growth assumptions edging from around 2.99% to about 3.01%, the Street narrative is shifting toward a cautiously optimistic, fairly valued stance. Read on to see how this evolving price target framework can help you stay ahead of the next turn in the story and keep updated as the narrative changes.

Stay updated as the Fair Value for Reckitt Benckiser Group shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Reckitt Benckiser Group.

???? Bullish Takeaways

Berenberg has inched its target up to 5,647 GBp, while Deutsche Bank has lifted its target to 5,700 GBp, signaling modestly improving confidence in Reckitt Benckiser Group’s ability to sustain steady growth from here.

The successive price target raises suggest analysts are rewarding the company’s execution and cost discipline, with incremental upgrades pointing to gradually strengthening conviction in its medium term revenue and margin trajectory.

Even with only Hold ratings in the latest notes, the upward drift in targets supports the view that the current fair value embeds a solid, if unspectacular, growth profile rather than a deterioration in fundamentals.

???? Bearish Takeaways

Both Berenberg and Deutsche Bank continue to rate the stock at Hold, indicating that, despite higher targets, they see limited upside from current levels and view valuation as broadly full.

The cautious stance implies that near term risks and execution hurdles remain in focus, with analysts signalling that much of the expected improvement in growth and profitability may already be reflected in Reckitt Benckiser Group’s share price.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Mucinex has expanded its portfolio with the launch of Mucinex Clear and Cool Saline Nasal Spray, a drug free, menthol boosted saline spray featuring a 2 in 1 nozzle that offers both Power Jet and gentle mist settings. It is now rolling out across major U.S. retailers alongside a Grand Central Station art installation to raise brand awareness.

Reckitt Benckiser Group has reaffirmed its 2025 guidance, reiterating expectations for like for like net revenue growth of 3% to 4%. This underscores management’s confidence in the medium term outlook despite persistent pressures on consumer spending and input costs.

New long term GASP Study data on extended release guaifenesin (Mucinex) in stable chronic bronchitis patients report clinically meaningful reductions in cough and sputum severity, better quality of life outcomes, and strong treatment adherence. The findings offer clinicians evidence based support for chronic adjunctive use and PRO based monitoring via CASA Q.

The fair value estimate has risen slightly from approximately £62.50 to about £63.15 per share. This reflects a modest uplift in the intrinsic value assessment.

The discount rate remains unchanged at 7.07%, indicating no shift in the assumed risk profile or cost of capital used in the valuation.

Revenue growth has increased marginally from around 2.99% to about 3.01%, suggesting a slightly more optimistic view on long term top line expansion.

The net profit margin has edged down fractionally from roughly 16.84% to about 16.83%, implying a near stable outlook for underlying profitability.

The future P/E multiple has risen slightly from about 19.6x to roughly 19.8x, signaling a modest rerating in expected earnings valuation.

Narratives on Simply Wall St are simple stories that connect your view of a company with the numbers behind it, from future revenue and earnings to margins and fair value. Each Narrative links Reckitt Benckiser Group’s business drivers to a forecast, then to a fair value you can compare with today’s share price to inform your own decision on whether to buy or sell. Narratives live in the Community page, are easy to follow, and update dynamically as new news, guidance, or earnings arrive.

Head over to the Simply Wall St Community and follow the Narrative on Reckitt Benckiser Group to stay on top of:

How emerging market expansion, product innovation, and premiumisation could influence growth and margins relative to the broader market.

Whether legal risks, slowing developed markets, and powerbrand concentration start to affect the path to higher profits.

How updated earnings forecasts, margin assumptions, and the implied forward P/E reshape the relationship between fair value and the current share price.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include RKT.L.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com